Related Experiment Videos
Statins and the role of nitric oxide in chronic heart failure
Stephan von Haehling1, Stefan D Anker, Eberhard Bassenge
1Department of Clinical Cardiology, National Heart & Lung Institute, Imperial College, School of Medicine, London, UK. stephan.von.haehling@web.de
Insights
Statins may treat heart failure by improving endothelial function and reducing inflammation. Lower doses might be effective for these cardiovascular benefits, distinct from cholesterol reduction.
Area of Science:
- Cardiovascular Science
- Pharmacology
Background:
- Endothelial dysfunction, characterized by nitric oxide (NO) deficiency, is central to cardiovascular diseases.
- Statins, primarily used for hypercholesterolemia, show potential in improving endothelial function through incompletely understood mechanisms.
Purpose of the Study:
- To explore the multifaceted mechanisms by which statins may ameliorate endothelial dysfunction.
- To investigate statins' potential therapeutic role in chronic heart failure, considering their anti-inflammatory and antioxidant properties.
Main Methods:
- Review of existing literature on statin mechanisms of action, including effects on nitric oxide synthase, Rho signaling, inflammation, and oxidative stress.
- Analysis of studies investigating statin impact on C-reactive protein and pro-inflammatory cytokines.
Main Results:
- Statins enhance nitric oxide synthase activity, potentially via Rho signaling inhibition.
- Statins exhibit anti-inflammatory effects, reducing C-reactive protein and pro-inflammatory cytokine induction.
- Evidence suggests statins may counteract oxygen free radical production.
Conclusions:
- Statins possess pleiotropic effects beyond cholesterol lowering, including improving endothelial function, reducing inflammation, and combating oxidative stress.
- These properties suggest statins could be beneficial in treating aspects of chronic heart failure, possibly at lower therapeutic doses.
Abstract:
Endothelial dysfunction plays an important role in a number of cardiovascular diseases. An important pathogenetic factor for the development of endothelial dysfunction is lack of nitric oxide (NO), which is a potent endothelium-derived vasodilating substance. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), originally designed to lower plasma cholesterol levels, seem to ameliorate endothelial dysfunction by a mechanism so far only partly understood. However, statins increase nitric oxide synthase activity. It has been speculated that this and other "side effects" of statin treatment are due to inhibition of Rho, an intracellular signalling protein that initiates Rho kinase transcription. Moreover, statins possess anti-inflammatory characteristics. Some statins have proven to lower plasma levels of C-reactive protein, which is induced by pro-inflammatory cytokines. Other statins have been demonstrated to directly inhibit pro-inflammatory cytokine induction. Finally, some data suggest that statins might be able to counterbalance an increased production of oxygen free radicals. Since chronic heart failure is accompanied not only by endothelial dysfunction, but also by pro-inflammatory cytokine activation and enhanced formation of oxygen free radicals, it is tempting to speculate that statins might be an ideal candidate to treat certain features of this disease. The doses needed to achieve the desired effects might be much lower than those needed to treat hypercholesterolemia.